Agios Executive and Leadership Team

Cecilia Jones, the Chief Financial Officer at Agios, directs all financial operations and strategic fiscal planning. Overseeing budgeting, forecasting, and capital allocation, Jones ensures robust financial health to support the company's drug development pipeline. This leadership role involves managing investor relations and communicating financial performance to stakeholders. By optimizing resource deployment, Cecilia Jones directly supports the advancement of novel therapies like PYRUKYND and pipeline candidates targeting rare diseases. The Chief Financial Officer's strategic guidance is crucial for sustained growth and market positioning in the biopharmaceutical sector, ensuring financial stability for ongoing research and development initiatives across the United States.

Ellen Lopresti, the Chief People Officer at Agios, architects the company's human capital strategy and cultivates a high-performance culture. Overseeing talent acquisition, development, and employee engagement, Lopresti ensures a skilled and motivated workforce dedicated to Agios's mission. This executive position involves fostering an inclusive environment that supports innovation in drug discovery and development. By championing organizational development, Ellen Lopresti directly contributes to the effective execution of strategies for bringing life-changing medicines to patients. The Chief People Officer's focus on people operations is fundamental to Agios's success in the competitive biopharmaceutical landscape, driving employee retention and fostering collaboration across all departments in Cambridge, Massachusetts.

James Burns, the Chief Legal Officer at Agios, provides strategic legal counsel and oversees all corporate governance matters. Directing the legal department, Burns manages intellectual property, regulatory compliance, and litigation, safeguarding the company's assets and interests. This critical role ensures adherence to stringent pharmaceutical regulations across the United States. By mitigating legal risks, James Burns directly supports the advancement of Agios's innovative therapies, including PYRUKYND and pipeline candidates. The Chief Legal Officer's expertise is essential for navigating the complex legal and regulatory frameworks inherent in drug development and commercialization, ensuring the company operates with integrity and compliance.

Sarah Gheuens, the Chief Medical Officer & Executive Vice President at Agios, spearheads clinical development and medical affairs strategies. Overseeing the design and execution of clinical trials for novel therapeutics, Gheuens drives the advancement of medicines like PYRUKYND and pipeline assets targeting rare genetic diseases. This senior leadership position involves translating scientific insights into effective patient treatments and ensuring medical excellence. By guiding clinical research, Sarah Gheuens directly impacts the successful progression of drug candidates through regulatory pathways. The Chief Medical Officer's deep medical expertise is paramount to Agios's mission of delivering transformative therapies, shaping the future of treatment for hemolytic anemias and other metabolic disorders.